A CD40 variant is associated with systemic bone loss among patients with rheumatoid arthritis

Autor: Rim Sghiri, Hana Benhassine, Khadija Baccouche, Meriem Ghozzi, Sarra Jriri, Zahid Shakoor, Adel Almogren, Foued Slama, Nadia Idriss, Zeineb Benlamine, Elyes Bouajina, Ramzi Zemni
Rok vydání: 2021
Předmět:
Zdroj: Clinical rheumatology. 41(6)
ISSN: 1434-9949
Popis: Little is known about genes predisposing to systemic bone loss (SBL) in rheumatoid arthritis (RA). Therefore, we examined the association between SBL and variants of genes playing a critical role in both immune response and bone homeostasis among patients with RA.IRAK-1 rs3027898, IRAK-2 rs3844283, IRAK-2 rs708035, IFIH1 rs1990760, CD40 rs48104850, TNFAIP3 rs2230926, and miR146-a rs2910164 were genotyped in 176 adult RA patients. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA).Low BMD was observed in 116 (65.9%) patients. Among them, 60 (34.1%) had low femoral neck (FN) Z score, 72 (40.9%) had low total femur (TF) Z score, and 105 (59.6%) had low lumbar spine (LS) Z score. Among all the SNPs assessed, only CD40 rs4810485 was found to be associated with reduced TF Z score with the CD40 rs4810485 T allele protecting against reduced TF Z score (OR = 0.40, 95% CI = 0.23-0.68, p = 0.0005). This association was confirmed in the multivariate logistic regression analysis (OR = 0.31, 95% CI = 0.16-0.59, p = 3.84 × 10This study for the first time ever demonstrated an association between a CD40 genetic variant and SBL among patients with RA.• CD40 rs4810485 GG genotype is associated with decreased BMD among patients with RA. • CD40 rs4810485 might serve as a genetic marker for SBL in RA. • CD40 genetic variations might be integrated in future development of more effective therapeutic interventions for prevention of SBL in RA.
Databáze: OpenAIRE